Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Nervous System Diseases | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Target |
Mechanism H1 receptor antagonists |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date03 Jul 2000 |
Target |
Mechanism DHPS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. FR |
First Approval Date15 Jun 1992 |
Target |
Mechanism VMAT2 inhibitors |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. AU |
First Approval Date23 Aug 1991 |
Start Date- |
Sponsor / Collaborator |
Start Date- |
Sponsor / Collaborator |
Start Date25 Mar 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Tetrabenazine ( VMAT2 ) | Movement Disorders More | Approved |
Silver sulfadiazine/Cerium nitrate ( DHPS ) | Burn infections More | Approved |
Betotastine besilate ( H1 receptor ) | Urticaria More | Approved |
RUS-350 ( SERT x VMAT2 ) | Huntington Disease More | Discontinued |
MBU-820 | Gastrointestinal Diseases More | Pending |